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Objectives: Dermatology Life Quality index (DLQI) is the most widely used health-related quality of life questionnaire in
dermatology. Little is known about existing questionnaire or scoring modifications of the DLQI. We aimed to
systematically review, identify, and categorize all modified questionnaire versions and scoring methods of the DLQI.
Methods: We performed a systematic literature search in PubMed, Web of Science, CINAHL, and PsychINFO. Methodologic
quality and evidence of psychometric properties were assessed using the Consensus-Based Standards for the Selection of
Health Measurement Instruments (COSMIN) and Terwee checklists.
Results: The included 81 articles reported on 77 studies using 59 DLQI modifications. Modifications were used for a combined
sample of 25 509 patients with 47 different diagnoses and symptoms from 28 countries. The most frequently studied diseases
were psoriasis, hirsutism, acne, alopecia, and bromhidrosis. The modifications were categorized into the following non-
mutually exclusive groups: bolt-ons or bolt-offs (48%), disease, symptom, and body part specifications (42%), changes in
existing items (34%), scoring modifications (27%), recall period changes (19%), response scale modifications (15%), and
illustrations (3%). The evidence concerning the quality of measurement properties was heterogeneous: 4 of 13 studies
were rated positive on internal consistency, 1 of 3 on reliability, 3 of 5 on content validity, 9 of 22 on construct validity, 6
of 6 on criterion validity, and 1 of 1 on responsiveness.
Conclusion: An exceptionally large number of DLQI modifications have been used that may indicate an unmet need for
adequate health-related quality of life instruments in dermatology. The psychometric overview of most questionnaire
modifications is currently incomplete, and additional efforts are needed for proper validation.
Keywords: alternative scoring, bolt-on, Dermatology Life Quality Index, psoriasis, psychometrics, questionnaire modifications,
skin disease, systematic review.
VALUE HEALTH. 2021; 24(8):1158–1171Introduction
The Dermatology Life Quality Index (DLQI) was the first skin-
specific health-related quality of life (HRQoL) questionnaire.1 In
the past 25 years since its publication, it has become by far the
most frequently used instrument to measure HRQoL in derma-
tology.2 It has been translated to .110 languages and now it is
used in .40 skin conditions worldwide. Measurement properties
of the DLQI, such as validity, reliability, and responsiveness to
change were reported by more than a 100 independent studies.3 It
is widely used in both clinical practice and research settings,
including randomized controlled trials, patient registries, and
national treatment and reimbursement guidelines.4-7
Many generic or skin-specific HRQoL questionnaires have
multiple versions developed by the copyright holders allowing
physicians and researchers to decide upon which measure would
be best suited for their purpose. These versions may differ in
terms of their response scales (eg, the EQ-5D offers a 3-level15 - see front matter Copyright ª 2021, ISPOR–The Professional Society for
cess article under the CC BY-NC-ND license (http://creativecommons.org/lic[EQ-5D-3L] and 5-level [EQ-5D-5L] version for adults),8 the
number of questionnaire items (eg, Skindex-29, –16)9 or recall
period (eg, Short-Form 36 [SF-36] is available in a chronic, 4-week
and in an acute, 1-week format).10 In recent years, adding new
“bolt-on” items to existing questionnaires has also become pop-
ular to develop disease-specific questionnaires and, as such, to
improve sensitivity to change. For example, a psoriasis-specific
version of the EQ-5D-5L questionnaire (EQ-PSO) has been devel-
oped by adding 2 additional dimensions, “skin irritation” and
“self-confidence” to the existing 5 dimensions.11,12 Furthermore,
alternative scoring algorithms are often created for HRQoL ques-
tionnaires, with the aim of improving psychometric properties or
changing the weighting of items (eg, different ways of scoring are
available for the SF-36).10,13-15
Currently, the DLQI has one official version that has maintained
its original form since 1994. Little is known about existing ques-
tionnaire modifications or scoring methods of the DLQI. Until now
there has been no systematic review summarizing the attempts toHealth Economics and Outcomes Research. Published by Elsevier Inc. This is an
enses/by-nc-nd/4.0/).
PATIENT-REPORTED OUTCOMES 1159modify the DLQI. The present systematic review, therefore, aimed
to (1) identify and categorize all modified questionnaire versions
and scoring methods of the DLQI; (2) evaluate the measurement
properties of these questionnaires and scorings, and (3) recom-
mend validated tools for use in future research and clinical
practice.Methods
Description of DLQI
The DLQI was designed to be used in patients $16 years. It
consists of 10 items that encompass the following 6 aspects of
HRQoL: symptoms and feelings, daily activities, leisure, work and
school, personal relationships, and treatment.1 All questions have
a 1-week recall period. The 10 items of the questionnaire are rated
on a 4-point scale (“not at all” or “not relevant” = 0, “a little” = 1, “a
lot” = 2 and “very much” = 3), yielding a total score of 0 to 30. A
higher total score represents a greater impairment of HRQoL.
Design, Data Sources, Search Strategy
The protocol of this systematic review was registered in
PROSPERO (https://www.crd.york.ac.uk/prospero/), under number
CRD42020151988. MEDLINE via PubMed, PsycInfo, and CINAHL
(via EBSCO) and the Web of Science were searched from January 1,
1994 (DLQI creation), to July 26, 2019. The search terms consisted
of “Dermatology Life Quality Index” or “DLQI” or “Dermatology
Quality of Life Index” or “DQLI.” Citation tracking of the eligible
studies was carried out by hand searching reference lists. Google
Scholar was also searched (last on September 15, 2019) with the
full names of the questionnaire versions identified during the
study, and the first 100 hits for each instrument were screened for
inclusion. No restrictions for language were applied. The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
guideline was followed for reporting this systematic review.16
Study Selection, Inclusion, and Exclusion Criteria
Studies were included in this review if used a modified ques-
tionnaire or scoring to DLQI in any disease (dermatological or
other) in any patient population (children or adults). Assessing
any measurement property of the modified questionnaire was not
an entry requirement. Studies were excluded if (1) they were
published as a dissertation, review, editorial, guideline, or con-
ference abstract; (2) reported on the original DLQI or its cross-
cultural adaptation in any language, and (3) reported on the
original or a modified version of the Children’s Dermatology Life
Quality Index (CDLQI) or Family Dermatology Life Quality Index.
Inclusion an exclusion criteria were applied by 2 reviewers (F.R.
and A.S.) independently to titles and abstracts retrieved with
searches to identify relevant studies. Potentially eligible full-texts
were also screened independently by the 2 reviewers. Any dis-
agreements about inclusion were resolved by consensus with a
third reviewer (V.B.).
Data Extraction
Characteristics of the study population (patient number, age,
and sex distribution), the disease (diagnosis, disease duration, and
disease severity) and instrument administration (study design,
clinical settings, number of centers, country, and language version
of the used questionnaire) were extracted into Microsoft Excel
2016 spreadsheet. The following questionnaire characteristics
were extracted in each study: questionnaire or scoringmodification performed, number of items, score range of the items
and total scores recall period and target population (adults or
children). DLQI modifications were categorized into the following
nonmutually exclusive groups:
1. Scoring modifications. Any modifications that change how the
response levels are scored or total DLQI score is calculated. This
includes alternative scorings to the original DLQI as well as
modifications that apply to any modified DLQI questionnaire.
Note that all response scale modifications automatically imply
a change in scoring, with the exception of removing or adding
“not relevant” response options to the questionnaire.
2. Item modifications (bolt-on, bolt-off, bolt-on and off). Bolt-ons
are additional questionnaire item(s) appended to the original
questionnaire. Bolt-offs are DLQI items that are dropped. Bolt-
on and offs represent the combination of bolt-ons and bolt-offs,
whereby new items are added to and certain items are
removed from the DLQI at the same time.
3. Recall period modifications. Changes that shorten or lengthen
the recall period of DLQI.
4. Changes made in existing items. Modifications that change the
wording of an existing item but not the entire item.
5. Response scale modifications. Changes in response scale of the
items.
6. Body part, disease or symptom specifications. “Skin” is
replaced by another word or phrase referring to a body part,
disease, or symptom throughout the entire questionnaire or in
certain items.
7. Illustrations. Changes that add pictorial illustrations to either
the questions or response scale of the DLQI.
8. Changes made to the target population of the questionnaire.
Modifications that change the target population of the DLQI to
children aged ,16 years.Assessment of the Methodologic Quality of the Included
Studies
We rated the methodologic quality for each questionnaire in
each included study separately using the COnsensus-based Stan-
dards for the Selection of Health Measurement INstruments
(COSMIN) Risk of Bias checklist.17 The checklist includes 9 aspects
of validity, reliability, and responsiveness. Each aspect consists of 5
to 18 items to be assessed. These items are scored in a standard-
ized way on a 4-point scale (ie, “poor,” “fair,” “good,” or “excel-
lent”).18,19 The overall rating of the quality of each study was
determined using “the worst score counts” principle.
Evaluation of the Measurement Properties
The quality of measurement properties of all identified ques-
tionnaire modifications or scorings were evaluated according to
the quality criteria adapted based on Terwee et al20 and Prinsen
et al21 (Appendix 1 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.02.006). These criteria apply to the
following properties: internal consistency, test–retest reliability,
measurement error, content validity, structural validity, construct
validity, criterion validity, cross-cultural validity and measurement
invariance, responsiveness, floor and ceiling effects, and inter-
pretability. All properties represented by one item that were rated
as positive (1), intermediate (?), negative (2), or no information
available (0). Both methodologic and quality assessment were
done by 2 reviewers (F.R. and V.B.) separately and reached
consensus through discussion.
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Inclusion of Relevant Studies
The electronic database search yielded 2104 records, 1663 of
which were full-text articles retrieved, and 55 finally deemed
eligible. The majority of full texts were excluded, as they used the
original DLQI without any modifications in the questionnaire or its
scoring. In addition, 26 eligible articles were identified by tracking
the reference lists of included articles and by searching Google
Scholar. Thus, 81 articles reporting on 77 studies were included in
this systematic review (Fig. 1). The 77 studies contained infor-
mation on overall 59 questionnaire or scoring modifications of the
DLQI. To make a clear distinction, “studies,” “articles,” and
“modifications” are hereafter denoted as N, n, and k, respectively.
Citations for each study are provided in Tables 1 to 4 and
Appendices 2 to 10 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.02.006.Figure 1. Study flow diagram.
CDLQI indicates Children’s Dermatology Life Quality Index; FDLQI, Family Derm
of Science.Characteristics of the Included Studies
The characteristics of the study populations are presented in
Appendix 2 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.02.006. Sample sizes of the included
studies varied widely, ranging from 1 to 9845 patients. The
cumulated sample size was 25 509 participants, 99% of which
were patients, and 1% healthy controls. A total of 47 different
diagnoses/symptoms were studied (Table 1). The most
frequently studied diseases were psoriasis (n = 16, 21%), acne
(n = 6, 8%), hirsutism (n = 6, 8%), alopecia (n = 5, 6%), and
bromhidrosis (n = 5, 6%).
Most study designs were cross-sectional studies (N = 35, 45%),
noncontrolled clinical trials (N = 19, 25%), or randomized
controlled trials (N = 11, 14%). The majority of studies included
outpatients (N = 64, 83%). Approximately one-third of the studies
were multicenter (N = 24, 31%; Appendix 3 in Supplemental Ma-
terials found at https://doi.org/10.1016/j.jval.2021.02.006).atology Life Quality Index; DLQI, Dermatology Life Quality Index; WoS, Web
Table 1. Diagnoses/symptoms in which DLQI modifications were used.
Studies (N)* % Patient number† % Modifications (k) % References
Acne 6 8 3721 15 5 8 22,29,30,33,83,101
Alopecia 5 6 496 2 5 8 24,45,54,80,102
Asteatotic eczema 1 1 5 ,1 1 2 103
Atopic dermatitis 4 5 335 1 3 5 22,27,29,104
Bromhidrosis 5 6 494 2 2 3 48,105-108
Burn 1 1 49 ,1 1 2 109
Contact dermatitis 4 5 1481 6 4 7 29,46,81,110
Cutaneous larva migrans 1 1 91 ,1 2 3 94,95
Darier’s disease 1 1 1 ,1 1 2 111
Dermatitis (unspecified) 2 3 1294 5 2 3 22,29
Discoid lupus 1 1 7 ,1 1 2 29
Eczema (unspecified) 2 3 1287 5 2 3 22,83
Filarial lymphedema 2 3 118 ,1 2 3 31,112
Folliculitis 1 1 1 ,1 1 2 83
Hand eczema 2 3 2319 9 1 2 23,113
Hidradenitis suppurativa 3 4 264 1 2 3 83,114,115
Hirsutism 6 8 293 1 3 5 39,116-120
Hyperhidrosis 4 5 207 1 2 3 37,50,83,121
Leg ulcers 1 1 17 ,1 1 2 29
Lipodystrophia 1 1 84 ,1 1 2 122
Melasma 1 1 8 ,1 1 2 29
Morphea 1 1 101 ,1 1 2 72
Nodular prurigo 1 1 6 ,1 1 2 29
Obesity 1 1 79 ,1 1 2 115
Pachyonychia congenita 1 1 76 ,1 1 2 25
Pemphigus 2 3 115 ,1 1 2 29,72
Photoaging 1 1 35 ,1 1 2 123
Photodermatoses 3 4 949 4 3 5 43,79,82
Pigment disorder (unspecified) 1 1 2 ,1 1 2 83
Port-wine stains 1 1 197 1 1 2 32
Pruritus 4 5 196 1 3 5 27,103,124,125
Psoriasis 16 21 5188 20 15 25 22,24,27-29,49,69,72,74,
83-87,115,126-128
Rosacea 1 1 2 ,1 1 2 83
Sarcoidosis 1 1 1 ,1 1 2 83
Scabies 2 3 217 1 4 7 53,93
Scleroderma 1 1 1 ,1 1 2 83
Seborrheic dermatitis 2 3 198 1 2 3 41,103
Sialorrhoea 2 3 13 ,1 2 3 51,62
Skin toxicity after chemotherapy 3 4 547 2 3 5 40,61,129
Skin tumor (unspecified) 1 1 4 ,1 1 2 83
Tinea capitis 1 1 10 ,1 1 2 29
Tungiasis 1 1 50 ,1 1 2 52
Urticaria 4 5 843 3 4 7 22,27,29,130
Vaginal candidiasis 2 3 303 1 2 3 131,132
Vascular malformation 1 1 20 ,1 1 2 28
Vitiligo 3 4 283 1 3 5 32,38,133
continued on next page
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Table 1. Continued
Studies (N)* % Patient number† % Modifications (k) % References
Warts 3 4 312 1 2 3 26,29,47
Other (unspecified) 6 8 2934 12 5 8 22,29,42,44,83,103
Healthy controls 3 4 255 1 3 5 25,29,95
Total‡ 77 25 509 59
DLQI indicates Dermatology Life Quality Index.
*The articles by Kim et al (2014,85 2015,86 and 201587) used the same dataset and therefore considered one study. The articles by Barbieri and Gelfand (201974 and
201973) used the same dataset and therefore considered one study. The article by Schuster et al (201194) and Shimogowara et al (201395) used the same dataset
and therefore considered one study.
†The patient populations of the Rencz et al (201869 and 201972) studies overlapped.
‡Figures in the number of studies and number of modifications columns do not add up as one study may have included patients with various diseases and symptoms.






Scoring modifications 20 26 16 27
Alternative scoring for the original
questionnaire*
8 10 4 7 25,69,72-74,114,124,125,127
Other changes in scoring 12 16 12 20 22-24,31,38,46,51,61,113,115,130,133
Item modifications 28 36 28 48
Bolt-on 4 5 4 7 29,103,118,126
Bolt-on and off* 14 20 17 29 25,26,38,46,47,51-53,93-95,110,115,120,133
Bolt-off 10 13 7 12 22,23,27,28,61,102,109,113,122,130
Recall period modifications 19 25 11 19
Before the Botox treatment 2 3 1 2 50,111
Before the surgical treatment 2 3 1 2 48,106
Generally 2 3 1 2 26,47
Last month 1 1 1 2 112
Last 2 mo 1 1 1 2 33
Last 6 mo 1 1 1 2 46
Last year* 9 12 3 5 43,45,79-87
Over your lifetime with psoriasis* 1 1 1 2 85-87
Nowadays compared with before the
phototherapy
1 1 1 2 133
Changes in existing items 28 36 20 34
Change in one item 16 21 11 19 26,32,33,37,47,48,50,104-108,111,121,122,128
Change in more items 12 16 9 15 22,24,25,42,49,51-54,93,115,120
Response scale modifications 10 13 9 15
Change related to the “not relevant”
response option
6 8 4 7 26,29,47-49,51
Frequency scale 1 1 2 3 115
Rating scale 1 1 1 2 46
Other modifications 2 3 2 3 38,133
Disease/symptom/body part
specifications†
30 39 25 42
Disease specification* 11 14 10 17 25,26,30,33,47,52,54,85-87,112,115,131
Symptom specification 14 18 9 15 25,27,28,39,40,45,51,101,109,116,117,119,122,132
Body part specification 7 9 7 12 25,31,41,49,102,120,129
Illustrations 2 3 2 3
Illustrated questions 1 1 1 2 44
continued on next page







Illustrated response options 1 1 1 2 52
Changes in the target population 4 5 4 7
Children* 4 5 4 7 52,53,93-95
Total‡ 77 59
DLQI indicates Dermatology Life Quality Index.
*The articles by Kim et al (2014,85 2015,86 and 201587) used the same dataset and therefore considered one study. The articles by Barbieri and Gelfand (201974 and
201973) used the same dataset and therefore considered one study. The articles by Schuster et al 201194 and Shimogowara et al (201395) used the same dataset
and therefore considered one study.
†The article by Abbas et al (201525) used 3 different disease, symptom and body part specifications; therefore, the total number of disease, symptom, and body part
specifications is 25 that have been used in overall 30 studies.
‡The sum of percentages is.100%, as one questionnaire modification may contain more than one changes. For example, a bolt-off may also change the response scales
of the questions etc.
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different languages, with English being the most common (N = 23,
30%; Appendix 4 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.02.006). The most frequently administered
non-English questionnaires were Chinese, Danish, German, Japa-
nese, and Persian. The studies originated from 28 different coun-
tries. The most commonwere the UK (N = 9, 12%) and China (N = 8,
10%; Appendix 5 in Supplemental Materials found at https://doi.
org/10.1016/j.jval.2021.02.006).
Modified DLQI Questionnaires and Scorings
The entire collection of these questionnaire or scoring modi-
fications is available in Appendix 6 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2021.02.006. Overall, 7 (9%)
studies used more than one questionnaire modification. The ma-
jority of the 59 modifications were item modifications (k = 28,
48%) or disease, symptom, and body part specifications (k = 25,
42%; Table 2). Among the item modifications, there were 4 (7%)
bolt-ons, 7 (12%) bolt-offs, and 17 (29%) bolt-on and bolt-offs. The
number of items in DLQI modifications ranged between 3 and 20
(Appendix 7 in Supplemental Materials found at https://doi.org/1
0.1016/j.jval.2021.02.006). The majority of bolt-on items con-
cerned social life (k = 9) or mental health (k = 8; Table 3). Overall,
25 different disease, symptom, and body part specifications were
identified, only one of which, “acne” was used in more than one
modification (Appendix 8 in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2021.02.006).
Overall, 15 (27%) different scoring modifications were iden-
tified, 4 (7%) of which were alternative scorings to the original
DLQI questionnaire. Recall period was changed in 11 (19%)
questionnaires to 9 different time frames, the most frequent of
which was the past year (k = 3). Change in existing items
occurred in 20 (34%) questionnaires. The most common wording
changes in existing DLQI items were replacing “self-conscious” in
item 2 with “ashamed” (k = 5), and removing the word “social”
from “social and leisure time” in item 5 (k = 4; Table 4). Other
modification types included response scale changes (k = 9, 15%),
changes made to the target population (ie, children; k = 4, 7%)
and pictorial illustrations (k = 2, 3%). A total of 10 (17%) modifi-
cations appeared in multiple studies: last year DLQI (N = 7),
bromhidrosis or hyperhidrosis-specific DLQI (N = 6), hirsutism-
specific DLQI (N = 4), DLQI-R scoring (N = 3), DLQI-Q1 scoring
(N = 3), pruritus-related quality of life index (N = 3), before sur-
gical treatment DLQI (N = 2), before Botox DLQI (N = 2), Rasch-
calibrated DLQI for hand eczema (N = 2), and viral wart-specific
DLQI (DLQI-VW; N = 2).Methodologic Quality of Studies (COSMIN Criteria)
Overall, 29 (36%) of the included 81 articles presented infor-
mation on the measurement properties of DLQI modifications
according to the COSMIN checklist (Appendix 9 in Supplemental
Materials found at https://doi.org/10.1016/j.jval.2021.02.006).
Overall, 25 (31%) publications applied classical test theory
methods to evaluate measurement properties, 3 used item
response theory,22-24 and one used both.25 The overall methodo-
logic quality of the articles was generally weak. There were only 3
modifications that received at least one “good” or “excellent”
rating. The most frequently assessed measurement properties
were hypothesis testing (n = 21, 26%), internal consistency (n = 10,
12%), and criterion validity (n = 5, 6%). Content validity (n = 5, 6%),
reliability (n = 3, 4%), structural validity (n = 3, 4%), cross-cultural
validity (n = 1, 1%), and responsiveness (n = 1, 1%) were examined
for a few questionnaires. There were no publications that reported
measurement error.
Measurement Properties of DLQI Modifications (Terwee
Criteria)
Sixty-four (79%) of the included 81 articles presented infor-
mation on the measurement properties of the questionnaire or
scoring modifications according to the Terwee criteria (n = 29, 36%
without floor and ceiling effects and interpretability). Internal
consistency was rated as positive for 4 questionnaires and inter-
mediate for 9 others (Appendix 10 in Supplemental Materials
found at https://doi.org/10.1016/j.jval.2021.02.006). Cronbach’s a
and person separation index for these modified questionnaires
ranged from 0.67 to 0.8725-33 and from 0.68 to 0.87, respec-
tively.22-24,30 Evidence on reliability was available for 3 articles, 1
was rated as positive, while 2 of them were intermediate. Content
validity was assessed for 5 articles (3 positive and 2 intermediate).
There was positive evidence for structural validity in 2 publica-
tions, intermediate in 2 publications, and negative in 2 others.
Construct validity was assessed for 22 articles (9 positive, 7 in-
termediate, and 6 negative). Good criterion validity with the
original DLQI was described for 6 publications. Responsiveness
was tested only in one study with positive results for DLQI-R
scoring. Evidence for floor and ceiling effects was reported for
24 (30%) articles, 7 of which were rated as positive, 14 as inter-
mediate, and 2 as negative. Furthermore, in one article, the DLQI-R
was rated as positive, while the DLQI-SF as intermediate for floor
and ceiling effects. For interpretability, none of the articles were
rated as positive, but a total of 47 (58%) were graded as
intermediate.






Daily activities 7 39 6 29
Disease making the living area messy or smelly 1 6 1 5 51
Lost time due to skin disease/ time spent to apply treatment or make-up to
camouflage lesions
5 28 4 19 26,47,120,126,133
Playing 1 6 1 5 93
Disease-specific symptoms 2 11 1 5
Bleeding from warts 2 11 1 5 26,47
Pain due to warts 2 11 1 5 26,47
Functioning 6 33 6 29
Coughing/choking 1 6 1 5 51
Sleeping* 4 22 4 19 25,46,52,94,95
Speaking 1 6 1 5 51
Walking 1 6 1 5 52
General health 2 11 2 10
Civil rights equivalent to that of a healthy citizen’s 1 6 1 5 38
General rating of health 1 6 1 5 133
General rating of health compared with before the phototherapy 1 6 1 5 133
Influence on life 1 6 1 5 133
Mental health 8 44 8 38
Anxiety 1 6 1 5 29
Being annoyed/irritable 1 6 1 5 46
Being frustrated 3 17 2 10 26,46,47
Being overwhelmed by the skin problem 1 6 1 5 38
Depression/inferiority complex 3 17 3 14 29,46,93
Effect on spirituality 1 6 1 5 38
Feeling uncomfortable 1 6 1 5 46
Getting upset 1 6 2 10 115
Insecurity/negative feelings 1 6 1 5 133
Worrying about infecting others 1 6 1 5 46
Social life 9 50 9 43
Being teased* 3 17 3 14 53,93-95
Fear of negative appraisal by others 2 11 1 5 26,47
Feeling stared at by people in the neighborhood 1 6 1 5 133
Getting married 1 6 1 5 38
Interactions 1 6 2 10 115
Performing prayers publicly 1 6 1 5 38
Physical health and emotional problems inhibiting social activities with
friends, family and others
1 6 1 5 133
Playing a role in finding new friends/relationship 1 6 1 5 133
Social exclusion 1 6 1 5 52
Therapy-related 4 22 3 14
Alcohol/medication use 1 6 1 5 25
Frustrated with current treatment 2 11 1 5 26,47
Frustrated with past treatment 2 11 1 5 26,47
Herbal medicine therapy 1 6 1 5 103
Work and financial problems 5 26 4 19
Disease interferes with daily work 2 11 2 10 25,46
Financial problems/costs of disease/costs of treatment 4 22 3 14 26,46,47,126
Using hands at work 1 6 1 5 46
continued on next page







Worrying about being fired 1 6 1 5 46
Other (unspecified) 1 5 1 5 118
Total 18 21
DLQI indicates Dermatology Life Quality Index.
*The articles by Schuster et al (201194) and Shimogowara et al (201395) used the same dataset and therefore considered one study.
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This systematic review identified 81 eligible articles that
described 59 questionnaire modifications and alternative scorings
of the DLQI. These modifications have been administered in .40
different skin conditions covering almost the entire spectrum of
dermatology. The results indicate that approximately 2% to 4% of
all published DLQI studies used modified DLQI questionnaires.
Most HRQoL questionnaires, including the DLQI, are copy-
righted to ensure the developers’ rights to their work (ie, repro-
ducing and distributing it, preparing derivative works) as well as
to retain the integrity of validated and authorized version of the
original questionnaire.34-36 As HRQoL measures are often used as
endpoints in clinical trials, for health-related decisions (eg, choice
of treatment), reimbursement decisions and labelling claims by
regulatory bodies, such as the US Food and Drug Administration
and the European Medicines Agency, maintaining quality stan-
dards is paramount. Users therefore are not allowed to change the
content, wording or format of the questionnaire (eg, instructions,
questions, and their order, response options, or recall period). Any
modifications require a formal approval from the copyright
holders, otherwise it is considered a copyright infringement.36 The
only exceptions are alternative scoring methods that use the
original questionnaire.
Out of the 55 modifications that would theoretically require
permission from the copyright holders (ie, not alternative scor-
ings), we identified 8 (14.5%) modifications for which the authors
explicitly stated to have obtained permission to alter the
DLQI.25,29,37-42 Furthermore, Professor Andrew Finlay, developer of
the DLQI is a co-author in further 4 (7.3%) modifications; thus,
these were carried out with his consent.30,43-45 For the rest of the
modifications (k = 43, 78%), the authors did not declare if they had
a permission to modify the DLQI. For 11 (20%) modifications, the
authors published a full reproduction of the modified question-
naire38,44,46-54; however, only 2 of these indicated having received
approval for reproduction from the copyright holders.38,44
Studies reporting on cross-cultural adaptations of the original
DLQI in any language were excluded from our review. In many
non-Western countries, for example, the word “partner” in item 8
of the DLQI has been replaced with “spouse,”55-57 or in Spanish,
the word “garden” in item 3 was replaced with “terrace.”58
Furthermore, in many languages (eg, Dutch, German, French,
Italian, and Spanish) the recall period of the questionnaire is
expressed in days (“7 days”) compared with the original ques-
tionnaire that uses “last week.” Given that the DLQI is used in
more than 110 languages worldwide, very likely many similar
subtle differences in wording may be present across the different
language versions. These alterations are different from those
summarized in our review, as these are typically authorized by the
copyright holders and aim to ensure the conceptual equivalence
between the source language and the target language as well asthe cultural relevance of the questionnaire for the target popula-
tion. We identified a total of 25 DLQI modifications that replaced
“skin” with a body part (eg, face), disease (eg, psoriasis) or
symptom (eg, pruritus). These may be considered very minor
modifications that are unlikely to result in the questionnaire being
answered differently by most patients. Nevertheless, in principle,
in patients with more than one dermatological condition, that is
not uncommon, these modifications may narrow down the
breadth of problems captured by the DLQI.
Drawing upon an existing, validated questionnaire, such as the
DLQI, may simplify the process of developing a new question-
naire.59 However, HRQoL questionnaires lose their validity,
comparability of scores and reliability if any word is changed.60
Thus, every questionnaire or scoring modification is required to
be revalidated, no matter whether the entire content or only one
word is altered. Notwithstanding, it seems that researchers often
misunderstand this practice and assume that there is no revali-
dation requirement for questionnaire modifications. This is re-
flected in the large number of studies in which no psychometric
properties were described at all (64% according to the COSMIN
checklist).
The overall methodologic quality of the studies reported in the
included articles was heterogeneous, but mostly appraised as
weak. For certain studies, it was unclear precisely what modifi-
cations were made to the DLQI.61,62 The number of psychometric
properties addressed per questionnaire in each study was limited.
Thus, many data in the literature are lacking regarding the psy-
chometric properties of the DLQI modifications. There is a wider
body of literature on psychometric evaluation of modifications for
generic HRQoL measures. Examples include methods used to
identify bolt-on items for the EQ-5D using principal component
analysis, confirmatory factor analysis or pairwise choices,63-65
identification of the least fitting items through item response
theory for the Assessment of Quality of Life-8 (AQOL-8),66
increasing the number of response levels for the EQ-5D8 and
tests on measurement properties of a recall period change for the
SF-36.67 However, the majority of DLQI modification studies lag
behind these studies in terms of methodologic quality.
Positive evidence on measurement properties from more than
one study was available for only the DLQI-R scoring modification.
The DLQI-R adjusts the total score of the questionnaire for the
number of “not relevant” responses indicated by patients.68-71
Three cross-sectional studies and a clinical trial used the DLQI-R
in patients with psoriasis, pemphigus, and morphea.69,72-74 The
DLQI-R showed an improved informativity, responsiveness to
change, convergent validity with Psoriasis Area and Severity index
(PASI) and the generic health status measure, EQ-5D-3L, an
excellent criterion validity against the original DLQI and no floor
or ceiling effects. In addition, recent findings, published after the
close of the literature search for this systematic review, support its
validity in patients with psoriasis, hidradenitis suppurativa, and
Table 4. The most common changes in existing DLQI items.
DLQI
item





Item 1 Over the last week, how itchy,
sore, painful or stinging has your
skin been?
“Itchy, sore, painful or stinging”
was changed to “sweaty.”
7 27 2 11 37,50,105,107,108,111,121
“Itchy, sore, painful or stinging”
was removed.
1 4 1 6 25
“Stinging” was changed to
“burning.”
1 4 1 6 49
“Stinging” was changed to
“irritation or oils on your scalp.”
1 4 1 6 54
“If you have ingrown hair” was
added to the end of the
question.
1 4 1 6 120
Item 2 Over the last week, how
embarrassed or self -conscious
have you been because of your
skin?
“Self-conscious” was changed to
“insecure.”
1 4 1 6 49
“Frustration” was added. 1 4 1 6 54
“Self-conscious” was changed to
“ashamed”.
3 12 5 28 52,53,93
Item 3 Over the last week, how much
has your skin interfered with you
going shopping or looking after
your home or garden?
“Garden” was replaced with
“attending college or work.”
1 4 1 6 33
The word “garden” was
removed.
1 4 1 6 120
Item 4 Over the last week, how much
has your skin influenced the
clothes you wear?
“Hairstyle” was added to the
question.
1 4 1 6 32
“Clothing” was replaced with
“hairstyle,” and an extra
sentence was added: “Do you
need to wear a hat, wig, or
special hair type to cover the
thinner area?”
1 4 1 6 54
“Make-up” was added to the
question.
1 4 1 6 51
Item 5 Over the last week, how much
has your skin affected any social
or leisure activities?
“Social or leisure” was changed
to “spare-time.”
1 4 1 6 53
The word “social” was removed. 3 12 4 22 52,53,115
Item 6 Over the last week, how much
has your skin made it difficult for
you to do any sport?
“Hobbies” was added. 1 4 1 6 54
Item 7 Over the last week, has your skin
prevented you from working or
studying? If "No," over the last
week how much has your skin
been a problem at work or
studying?
The word “studying” or “school”
was removed.
3 12 3 17 53,93,128
The word “work” was removed
or “working or studying” was
changed to “school work.”
3 12 3 17 52,53,93
The 2 separate questions were
merged into one: “How much
has your skin been a problem at
work or studying?”
1 4 1 6 48
The question was rephrased as
“curtailed working or going out.”
1 4 1 6 51
continued on next page









Item 8 Over the last week, how much
has your skin created problems
with your partner or any of your
close friends or relatives?
The question was rephrased as
“interfered with socializing with
your spouse or friends?”
1 4 1 6 51
“Partner or any of your close
friends or relatives” was
changed to “relationships.”
1 4 2 11 115
“Partner or any of your close
friends or relatives” was
changed to “friendships.”
3 12 3 17 52,53,93
“Partner or any of your close
friends or relatives” was
changed to “social contacts.”
2 8 2 11 53,93
The question was rephrased as
“interfere with personal
relationships.”
2 8 1 6 26,47
Item 9 Over the last week, how much
has your skin caused any sexual
difficulties?
“Sexual difficulties” was
replaced by “problems in close
personal relationships.”
1 4 1 6 104
Item
10
Over the last week, how much of
a problem has the treatment for
your skin been, for example by
making your home messy, or by
taking up time?
“Making your home messy” was
changed to “interfering with
your daily schedule.”
1 4 1 6 120
“For example, by making your
home messy, or by taking up
time” was removed.
1 4 1 6 48,106
“The treatment for your skin
been, for example, by making
your home messy or by taking
up time” was replaced with “take
care of your pachonychia
congenita.”
1 4 1 6 25
“Making your home messy, or
by taking up time” was changed
to “making your clothing and
other articles messy or by taking
up time.”
1 4 1 6 49
The question was rephrased as
“caused living area to be smelly
and messy.”
1 4 1 6 51
“Treatment” was changed to
“attempts to solve problems due
to body changes.”
1 4 1 6 122
All
items
- The items were rephrased into
neutral frames, that is, not to
lead a respondent to consider
this as a negative phenomenon.
1 4 1 6 42
Total 26 18
Note. Table does not item splits performed in Rasch analyses.
DLQI indicates Dermatology Life Quality Index.
PATIENT-REPORTED OUTCOMES 1167vitiligo.75-77 It also has been reported that the DLQI score bands
are valid for the DLQI-R.78 The adoption of the DLQI-R scoring in
psoriasis treatment and reimbursement guidelines might hold the
potential to improve the access to systemic treatments for patients
who cannot comply with the DLQI benchmark criteria because one
or more questionnaire items are not relevant to them.69
We have identified 9 different recall period modifications of
the DLQI. All but one of these modifications extended the 1-weekrecall period of the original DLQI. Of these, LY-DLQI was the most
common by having been used in 7 independent studies,43,79-84
and another 2 studies (4 publications)45,85-87 applied a 1-year
recall period along with other modifications made. The LY-DLQI
allows to capture the long-term HRQoL impact of skin diseases
as well as to compare scores with those of the original DLQI. The
longer recall period may be adequate for conditions in which
changes in health status and symptoms are typically gradual, such
1168 VALUE IN HEALTH AUGUST 2021as in certain types of hair loss or if a disease occurs intermittently,
such as in case of many photodermatoses. Nevertheless, the
literature suggests that longer recall periods may be more sus-
ceptible to recall bias.88-90 Future validation is warranted to judge
the usefulness of the LY-DLQI, particularly in alopecias and
photodermatoses.
Since 1995, DLQI has an official, validated version for children,
the CDLQI.91,92 Yet we identified 5 questionnaires that modified
the adult DLQI to capture the HRQoL impact of skin disease on
children. These modifications were applied in patients with
cutaneous larva migrans, scabies, and tungiasis.52,53,93-95
Improving the awareness of the existence of child-specific
HRQoL instruments, such as CDLQI, Teenager’s Quality of Life,
and Skindex-Teen is recommended.96,97
Similarly, to other medical specialties, in dermatology, HRQoL
can be assessed by using both disease-specific and generic mea-
sures. In addition, dermatology-specific measures, including the
DLQI and the Skindex instrument family also are frequently
used.98 The rationale for the existence of these instruments arises
from the common patient-reported symptoms in many skin dis-
eases. However, 2 studies reported differential item functioning
for the DLQI between patients with different diagnoses implying
that the DLQI scores should not be compared across different
patient populations.22,24 Furthermore, some argued that the DLQI
is not able capture the full range of HRQoL in certain condi-
tions99,100 as also testified by the many bolt-on items identified in
this review. For example, sleep disturbance or mental problems
may contribute to the HRQoL impairment in many skin diseases
that remains unexplored by using the DLQI. Notwithstanding,
several studies showed evidence of favorable measurement
properties of the DLQI in several different dermatological condi-
tions that supports its legitimacy.96
Given the widespread use of the DLQI in clinical practice,
clinical trials, registries, and as a benchmark in treatment and
reimbursement guidelines,4-7 this systematic review offers prac-
tical implications for clinicians, guideline developers, regulatory
bodies, the industry, and decision makers in healthcare. One of the
most important determinants of the success of DLQI is that it
represents a uniform approach in assessing HRQoL of patients
with .40 different diagnoses. The methodologic standardization
ensures the comparability across all DLQI studies carried out in
any dermatological condition, and modifications may detract from
these advantages of the original questionnaire. Additionally,
poorly designed and not validated questionnaires may compro-
mise study outcomes and may give ground to “gaming” in medical
product-labeling and reimbursement claims. We suggest 2
possible strategies to improve the usefulness of modified DLQI
questionnaires. Firstly, higher methodologic standards should be
introduced for future studies aiming to modify the DLQI ques-
tionnaire. Secondly, instead of designing additional DLQI modifi-
cations, researchers may be encouraged to further refine and
validate the existing modifications, especially where initial vali-
dation produced positive evidence on measurement properties.
The collection provided in this review is intended to facilitate this
endeavor by aiding the selection of instruments for further
validation.
A limitation of this systematic review is that we used a search
strategy specifically targeting the DLQI. The use of this precise
filter appeared to be a reasonable choice, and a sensitive filter (eg,
all quality of life studies in dermatology) would have provided too
many hits for full-text screening. Thus, our review might have
missed a few studies with modified DLQI questionnaire versions
that did not mention DLQI in their abstracts or among their key-
words. To fill in potential data gaps, a reference tracking and a
complementary search were performed using Google Scholar thatidentified 26 additional studies. Another limitation is the appli-
cability of the COSMIN Risk of Bias17,19,21 that is widely used to
select the best available outcome measures for clinical studies but
seems less useful for assessing the methodological quality of
studies reporting on questionnaire modifications that are typically
experimental in nature. Developing guidelines and checklists to
assess the quality of patient-reported outcome measure modifi-
cations (eg, bolt-on, recall period modifications, and alternative
scorings) is warranted.
Conclusion
In conclusion, this systematic review provides a collection of
existing questionnaire and scoring modifications of the DLQI. Our
findings indicate an incomplete psychometric overview of these
DLQI modifications. The paucity of validation data does not
necessarily imply poor measurement properties; however, the use
of most DLQI modifications is not currently supported by solid
evidence. The 2 most promising modifications for further valida-
tion are the DLQI-R scoring and the DLQI-LY questionnaire.
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